Profile data is unavailable for this security.
About the company
Autobio Diagnostics Co., Ltd. is a China-based company and mainly engaged in development, manufacture and sales of diagnostics products. The Company's main products include gnostic products, microbiology detection products, and related devices. The immunodiagnostic products include microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. The microbiology detection products include training detection reagents, susceptibility detection reagents and rapid detection reagents. The device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers. The Company distributes its products in domestic markets.
- Revenue in CNY (TTM)4.50bn
- Net income in CNY1.30bn
- Incorporated1999
- Employees5.54k
- LocationAutobio Diagnostics Co LtdNo.87 Jingbei Yi Rd.National Eco, Zhengzhou, Henan 450016ZHENGZHOU 450016ChinaCHN
- Phone+86 37 186506868
- Fax+86 37 186506767
- Websitehttps://www.autobio.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 24.40bn | 4.41k | 151.33 | 3.44 | -- | 4.95 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 24.82bn | 2.57k | -- | 4.19 | -- | 15.24 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 25.77bn | 8.22k | 27.49 | 3.05 | -- | 2.95 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Bluestar Adisseo Co | 13.53bn | 327.58m | 26.23bn | 2.73k | 80.07 | 1.74 | -- | 1.94 | 0.1222 | 0.1222 | 5.04 | 5.63 | 0.6286 | 4.67 | 7.33 | 4,947,799.00 | 1.52 | 5.28 | 1.85 | 6.94 | 23.81 | 30.31 | 2.42 | 8.76 | 1.04 | 4.30 | 0.1325 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Autobio Diagnostics Co Ltd | 4.50bn | 1.30bn | 27.45bn | 5.54k | 20.93 | 3.10 | -- | 6.10 | 2.24 | 2.24 | 7.74 | 15.11 | 0.4066 | 2.08 | 4.27 | 811,768.30 | 11.81 | 12.59 | 14.50 | 15.79 | 64.76 | 61.62 | 29.04 | 26.96 | 2.81 | -- | 0.1035 | 46.40 | 0.0457 | 18.15 | 4.28 | 16.70 | 17.03 | 11.32 |
| Humanwell Healthcare Group Co Ltd | 24.67bn | 1.96bn | 28.53bn | 17.68k | 14.48 | 1.63 | -- | 1.16 | 1.21 | 1.21 | 15.25 | 10.73 | 0.6833 | 3.80 | 2.77 | 1,395,473.00 | 7.21 | 6.20 | 13.29 | 12.72 | 45.02 | 42.82 | 10.55 | 9.84 | 1.20 | 31.56 | 0.3293 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 2.48bn | 915.35m | 28.96bn | 1.04k | 31.64 | 6.70 | -- | 11.66 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Gan & Lee Pharmaceuticals | 2.61bn | 386.85m | 29.44bn | 4.48k | 72.92 | 2.66 | -- | 11.28 | 0.6716 | 0.6716 | 4.52 | 18.38 | 0.234 | 0.8926 | 10.97 | 582,412.30 | 3.47 | 8.30 | 3.71 | 8.83 | 72.29 | 85.39 | 14.83 | 26.44 | 7.74 | -- | 0.0006 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.67bn | 2.99bn | 30.42bn | 5.23k | 10.12 | 2.13 | -- | 3.15 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Data as of Jun 27 2024. Currency figures normalised to Autobio Diagnostics Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Geng Fund Management Co. , Ltd.as of 30 Sep 2023 | 14.81m | 2.53% |
| Hwabao WP Fund Management Co., Ltd.as of 29 Jan 2024 | 6.77m | 1.16% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 5.71m | 0.97% |
| UBS AG (Investment Management)as of 30 Sep 2023 | 4.12m | 0.70% |
| First Sentier Investors (UK) IM Ltd.as of 29 Feb 2024 | 2.73m | 0.47% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 2.66m | 0.45% |
| UBS SDIC Fund Management Co., Ltd.as of 30 Jun 2023 | 2.58m | 0.44% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 2.16m | 0.37% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.13m | 0.36% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 1.93m | 0.33% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
